Preliminary Development and Assessment of a MultiplexAssay for Human Papillomavirus Antibody Detection Using Commercial L1 Proteins
Researchers developed a preliminary Luminex-based multiplex assay to detect IgG and IgA antibodies against seven human papillomavirus types: HPV-6, 11, 16, 18, 35, 45 and 58. The assay used commercially available L1 proteins and was evaluated using a blinded proficiency panel.
The assay demonstrated strong performance for IgG detection, including 100% sensitivity and specificity for HPV-6, 11, 16, 18 and 58 at the evaluated thresholds. It also distinguished between high, intermediate, low and negative antibody-response groups. IgA results were more variable but showed a positive correlation with IgG.
The findings suggest this multiplex assay could provide a scalable, high-throughput method for evaluating type-specific HPV antibody responses and supporting population-level vaccine-immunity research. However, the authors emphasize that further standardization and validation are required before broader application.
Source: Aslanabadi et al., Journal of Clinical Laboratory Analysis, published September 1, 2026.
Bead-based approaches for increased sensitivity and multiplexing of CRISPR diagnostics
This study developed two bead-based CRISPR-Cas13 diagnostic technologies. The bbLuc reporter achieved up to 20-fold greater sensitivity than conventional fluorescence-based reporting, while bbCARMEN detected nine respiratory viral targets in parallel with limits as low as 2.5 copies per microliter of input RNA. Clinical testing demonstrated the platforms’ potential for sensitive, multiplexed pathogen detection. The study included excess human nasopharyngeal swab specimens supplied by Boca Biolistics.
Siddiqui SM, Welch NL, Nguyen TG, et al. Bead-based approaches for increased sensitivity and multiplexing of CRISPR diagnostics. Nature Biomedical Engineering. 2026;10:939–951.
Two technologies, one goal: Developing and evaluating anti-Zika virus NS1 antibodies using phage display and hybridoma technologies for diagnostic applications
Multilayer Plasmon Hybridization in Au–Ag–Au Nanoparticles Enables Extinction Amplification in Transport-Limited One-Step Confirmatory Syphilis Biosensing
Siemens Healthineers cross-platform verification: Analytical and clinical analysis of HIV Antigen/Antibody Combo assay across ADVIA Centaur and Atellica analyzers
A recent study published in the Journal of Clinical Virology Plus evaluated the analytical and clinical performance of the Siemens Healthineers HIV Antigen/Antibody Combo (CHIV) assay across the Atellica CI, Atellica IM, and ADVIA Centaur XP analyzers. Using more than 3,300 clinical samples, researchers demonstrated greater than 99% agreement between platforms, confirming comparable precision, sensitivity, and reliability for HIV serological testing. The study also showed 100% agreement across HIV seroconversion panels, supporting consistent early HIV detection. Boca Biolistics contributed well-characterized HIV-positive and HIV-negative serum specimens used in the analytical verification phase, highlighting the importance of high-quality biospecimens in diagnostic assay validation and regulatory studies.
Serologic biomarker discovery for differentiating Lyme disease from diseases with similar clinical symptoms using broad profiling of antibody binding
Zhang T, Baert L, Woodbury NW and Kelbauskas L
Soluble Immunoreactive Treponema Pallidum TP497 Angitens
Faatz, N., Djinović-Carugo, K., & colleagues. (2021).